<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003846</url>
  </required_header>
  <id_info>
    <org_study_id>99702</org_study_id>
    <secondary_id>COG-99702</secondary_id>
    <secondary_id>CCG-99702</secondary_id>
    <secondary_id>CDR0000067006</secondary_id>
    <nct_id>NCT00003846</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors</brief_title>
  <official_title>Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy
      use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral
      stem cell transplantation may allow doctors to give higher doses of radiation therapy and
      chemotherapy and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of radiation therapy, chemotherapy and
      peripheral stem cell transplantation in treating patients with primitive neuroectodermal
      tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety of postradiotherapy high-dose consolidation chemotherapy with
           peripheral blood stem cell (PBSC) support in patients with high-risk primitive
           neuroectodermal tumors.

        -  Determine the safety of delaying radiotherapy by approximately one month in these
           patients.

        -  Determine the maximum tolerated dose of thiotepa in these patients.

        -  Determine the toxic effects of intensive chemotherapy with PBSC support in these
           patients.

        -  Assess the time to hematopoietic recovery after PBSC infusion when intensive
           chemotherapy is used after craniospinal radiotherapy in these patients.

        -  Determine the overall and event-free survival of patients treated with this regimen.

      OUTLINE: This is a dose-escalation study of thiotepa during consolidation therapy.

        -  Induction: Within 31 days of initial surgery, patients receive induction therapy
           comprising vincristine IV on day 0, cyclophosphamide IV over 2 hours on days 0 and 1,
           and filgrastim (G-CSF) subcutaneously (SC) beginning on day 2 and continuing for at
           least 7-10 days. Peripheral blood stem cells (PBSC) are then collected.

        -  Chemoradiotherapy: After blood cell counts recover, and within 28 days of starting
           induction, patients begin chemoradiotherapy. Patients receive vincristine IV once weekly
           for 8 doses. Radiotherapy is administered 5 days a week, for 6 weeks, beginning within
           the same week as the start of vincristine.

        -  Consolidation: Therapy begins 4-6 weeks after the last radiation treatment in the
           absence of disease progression. The first and third course are the same and comprise
           vincristine IV on day 0, carboplatin IV over 1 hour on days 0 and 1, thiotepa IV over 3
           hours on days 2-4, and G-CSF SC daily beginning on day 7. PBSC are reinfused on day 7.
           The second course comprises vincristine IV on day 0, carboplatin IV over 1 hour on days
           0 and 1, cyclophosphamide IV over 2 hours on days 2 and 3, and G-CSF SC daily beginning
           on day 5. PBSC are reinfused on day 5. Each course lasts 21 days.

      For consolidation therapy, cohorts of 6-12 patients each receive escalating doses of thiotepa
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which
      no more than 2 of 12 patients experience dose-limiting toxicity.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 24-56 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Neupogen®</other_name>
    <other_name>G-CSF</other_name>
    <other_name>NSC#614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Paraplatin®</other_name>
    <other_name>CBDCA</other_name>
    <other_name>NSC#241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
    <other_name>Procytox®</other_name>
    <other_name>CPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TRIETHYLENETHIOPHOSPHORAMIDE</other_name>
    <other_name>THIOPLEX®</other_name>
    <other_name>TEPA</other_name>
    <other_name>NSC# 6396</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin®</other_name>
    <other_name>Vincasar®</other_name>
    <other_name>leucocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>NSC# 67574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven primitive neuroectodermal tumor (PNET) of one of the following
             types:

               -  Atypical teratoid/rhabdoid tumor

               -  Medulloblastoma

               -  Desmoplastic medulloblastoma

               -  Ependymoblastoma

               -  Medullomyoblastoma

               -  Spongioblastoma

               -  Spongioblastoma polare

               -  Primitive polar spongioblastoma

               -  Medulloepithelioma

               -  Neuroblastoma

               -  Pineoblastoma

          -  Posterior fossa PNET must be M1-3 or M0 with greater than 1.5 cm2 residual disease

          -  Non posterior fossa PNET and other types must be M0-3

               -  If M3, must show clear evidence of tumor on MRI

          -  No marrow involvement or other extraneural metastases

          -  No M4 disease

          -  No cord compression requiring emergency radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  3 to 21

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 150,000/mm^3 (no platelet transfusions)

          -  Hemoglobin at least 10 g/dL (red blood cell transfusions allowed)

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  AST or ALT less than 2.5 times ULN

        Renal:

          -  Creatinine clearance or glomerular filtration rate at least 70 mL/min

        Cardiovascular:

          -  Shortening fraction greater than 27% by echocardiogram OR

          -  Ejection fraction greater than 47% by MUGA

        Pulmonary:

          -  FEV_1/FVC greater than 60% except for children who:

               -  Are uncooperative

               -  Have no dyspnea at rest

               -  Have no exercise intolerance

               -  Have pulse oximetry greater than 94% on room air

        Other:

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Steroids for increased intracranial pressure allowed

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior urgent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No prior therapy for tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Stacy Nicholson, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Cancer Center at Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

